Ultragenyx’s UX111 gene therapy faces FDA delay due to facility issues; analysts adjust price targets amid uncertain resubmission timeline.
Latest Ratings for RARE
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | Morgan Stanley | Maintains | Overweight | |
| Feb 2022 | JP Morgan | Upgrades | Neutral | Overweight |
| Feb 2022 | Morgan Stanley | Maintains | Overweight |
